CSI Market
Sign In | Register

Halozyme Therapeutics Inc (HALO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access HALO quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Halozyme Therapeutics Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income316.89
Depreciation & amortization11.39
Amortization of Other Assets84.17
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories2.55
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment2.62
Share-based Compensation51.57
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Contract With Customer Liability Revenue Recognized-
Deferred Rent Payments0.95
Research And Development Asset Acquired Other Than Through Business Combination Written Off284.89
Debt Securities Available For Sale Realized Gain Loss-0.17
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-128.06
Increase (Decrease) in Accounts Payable and Accrued Liabilities6.21
Accrued Expense0.00
Recognition of Deferred Revenue0.00
Prepaid Expense and Other Assets-32.32
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities50.88
Discontinued operations0.00
Net Cash flow from Operating Activities651.56
Investing Activities
Capital Expenditures-6.97
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities, Debt722.25
Payments to Acquire Available-for-sale Securities, Debt-247.36
Payments for Tenant Improvements0.00
Payment To Acquire In Process Research And Development Net Of Cash Acquired-287.77
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Proceeds from Previous Acquisition-725.97
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-545.81
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-4.94
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-342.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net129.93
Proceeds From Stock Options Exercised And Restricted Stock Options-
Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised21.83
Payment For Capped Call Transactions-
Purchase Of Capped Call-
Payment Of Capped C Transactions-
Payment Of Capped Call Transactions-
Payment For Induced Conversion Of Convertible Debt-5.48
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents115.85
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-85.17
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow644.59
Total Cash Flow20.57
4 historic quarters locked

Sign in to unlock the full Halozyme Therapeutics Inc cash flow history.

Sign In Create Free Account

About Halozyme Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 17, 2026
  • Source: halo-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001159036-26-000024

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License